ArticleJournal of immunology (Baltimore, Md. : 1950)2017
Anti-PD-1 Antibody Treatment Promotes Clearance of Persistent Cryptococcal Lung Infection in Mice.
Article in Journal of immunology (Baltimore, Md. : 1950), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 53 citations in OpenAlex.
- New approaches for cryptococcosis treatment and prevention-a systematic review.Journal of thoracic disease · 2026Review
- Emerging evidence for anti-PD-1 and IFN-γ as adjunctive immunotherapy in invasive mold infections.mBio · 2026Article
- Combined anti-PD-1 and amphotericin B therapy reduces fungal burden and enhances control of murine paracoccidioidomycosis.Frontiers in cellular and infection microbiology · 2026Article
- Emergence, function, and therapeutic strategies to target the PD-1/PD-L1 immune checkpoint during pathogenic fungal infections.Virulence · 2025Review
- Immune Phenotypes in Patients With Invasive Mould Infection Support the Use of PD-1 Inhibition as Potential Treatment Option.Mycoses · 2025Observational
- Cryptococcal infection: host immunity, immune evasion and emerging immunotherapeutic strategies.Frontiers in cellular and infection microbiology · 2025Review
- Case Report: Immune checkpoint inhibitor exhibits dual benefits for a refractory lymphoma patient with disseminated mucormycosis.Frontiers in medicine · 2025Article
- Inbred Mouse Models inJournal of fungi (Basel, Switzerland) · 2024Review
- New anticancer therapeutics impact fungal pathobiology, infection dynamics, and outcome.PLoS pathogens · 2023Article
- Unmasking a fungal fire.PLoS pathogens · 2023Article
- Transcriptional profiling of a fungal granuloma reveals a low metabolic activity ofFrontiers in cellular and infection microbiology · 2023Article
- Connecting the Human Microbiome and Pancreatic Cancer.Cancer metastasis reviews · 2022Review
- Candida albicans evades NK cell elimination via binding of Agglutinin-Like Sequence proteins to the checkpoint receptor TIGIT.Nature communications · 2022Article
- Mitogen-activated protein kinase phosphatase-1 controls PD-L1 expression by regulating type I interferon during systemic Escherichia coli infection.The Journal of biological chemistry · 2022Article
- [Pneumocystis jirovecii Pneumonia in Patients with Lung Cancer: A Review].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022Review
- Checkpoint inhibitors as immunotherapy for fungal infections: Promises, challenges, and unanswered questions.Frontiers in immunology · 2022Review
- Case Report: Immune Checkpoint Blockade Plus Interferon-Γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis.Frontiers in immunology · 2022Article
- T cell responses to control fungal infection in an immunological memory lens.Frontiers in immunology · 2022Review
- Depletion of PD-1 or PD-L1 did not affect the mortality of mice infected with Mycobacterium avium.Scientific reports · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Activation of immunomodulatory pathways in response to invasive fungi can impair clearance and promote persistent infections. The programmed cell death protein-1 (PD-1) signaling pathway inhibits immune effector responses against tumors, and immune checkpoint inhibitors that block this pathway are being increasingly used as cancer therapy. The objective of this study was to investigate whether this pathway contributes to persistent fungal infection and to determine whether anti-PD-1 Ab treatment improves fungal clearance. Studies were performed using C57BL/6 mice infected with a moderately virulent strain of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.